Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Inmed Pharmaceuticals Inc (NQ: INM )

0.2659 -0.0270 (-9.22%)
Streaming Delayed Price Updated: 3:57 PM EDT, Oct 31, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Inmed Pharmaceuticals Inc

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Game-Changer In Epidermolysis Bullosa Treatment? Cannabis Compound Holds Promise
In a positive step for the treatment of the rare genetic dermatological condition known as epidermolysis bullosa (EB), InMed Pharmaceuticals Inc. (NASDAQ: INM) has published top-line data from its... 
Via Benzinga
Why Avid Bioservices Shares Are Trading Lower By Over 14%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) shares climbed 422% to $0.5572 after the company announced acquisition of Spyre Therapeutics and concurrent oversubscribed $210 million private... 
Via Benzinga
Why Are InMed Pharmaceuticals Stock Trading Lower Today
InMed Pharmaceuticals Inc (NASDAQ: INM) shares are trading lower after the company released safety and efficacy results from its Phase 2 clinical trial (755-201-EB) for  
Via Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc.’s (NASDAQ: INM) 755-201-EB Trial Demonstrates Clinically Important Results
Via Investor Brand Network
Study Unveils Rare Cannabinoid As Promising Hope For Alzheimer's, Parkinson's & Huntington's Treatment
The study focused on the potential of rare cannabinoids in the treatment of neurodegenerative diseases like Alzheimer's. According to the researchers behind the study, this breakthrough research opens... 
Via Benzinga
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Sponsored Research Presented at Canadian Neuroscience Meeting
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Sponsored Research Presented at Canadian Neuroscience Meeting
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Participate in Virtual Investor Events Next Week
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Plans to Participate in Virtual Investor Events Next Week
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO Featured in Upcoming Water Tower Research Fireside Chat
Via CannabisNewsWire
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO Featured in Upcoming Water Tower Research Fireside Chat
Via Investor Brand Network
InMed Pharmaceuticals Stock Trading Higher On Q3 Sales Growth Of 234%, Here Is What You Need To Know
InMed Pharmaceuticals Inc. (NASDAQ: INM) released its financial results for the third quarter of the fiscal year 2023 which ended March 31, 2023, revealing sales of $1 million, an increase of 234%... 
Via Benzinga
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update
Via Investor Brand Network
CannabisNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Q3 2023 Financial Results, Provides Business Update
Via CannabisNewsWire
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Concludes Enrollment for Phase 2 Trial Studying INM-755 Cannabinol Cream
Via Investor Brand Network
InMed Pharmaceuticals: Pushing Pharma Forward With Rare Cannabinoids
Jerry Griffin, VP of Sales & Marketing at BayMedica, Inc. – a subsidiary of InMed Pharmaceuticals Inc (NASDAQ: INM) – was a guest on Benzinga’s All Access. 
Via Benzinga
Why Bed Bath & Beyond Shares Are Trading Lower By Around 24%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start off the trading week with a breakdown of the biggest pre-market stock movers for Monday and what's behind that movement! 
Via InvestorPlace
Despite Global Economic Pressures, InMed Pharma's Accomplishments In 2022 Could Be A Catalyst For Further Growth In 2023
InMed Pharmaceuticals Inc. (NASDAQ: INM), a biopharmaceutical company that is dedicated to advancing research and therapies for a wide range of medical conditions, has reported that it has made some... 
Via Benzinga
BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Peer-Reviewed Study Results Published
Via Investor Brand Network
Rare Cannabinoids Could Help Treat Atopic Dermatitis, Psoriasis, Pruritus And Acne: New Study
InMed Pharmaceuticals Inc. (NASDAQ: INM) announced that a peer-reviewed scientific study entitled "Rare phytocannabinoids exert anti-inflammatory effects on human keratinocytes via the endocannabinoid... 
Via Benzinga
Life Sciences Virtual Investor Forum: Presentations Now Available for Online Viewing
Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
InvestorNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) CEO to Present at Two March Investor Events
Via Investor Brand Network
Life Sciences Virtual Investor Forum Agenda Announced for March 9th
Company Executives Share Vision and Answer Questions Live at VirtualInvestorConferences.com 
From Virtual Investor Conferences
Via GlobeNewswire
TinyGemsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Releases Q2 2023 Financial, Corporate Report
Via Investor Brand Network
InMed Pharmaceuticals Q2 FY23 Revenue Grows 77% YoY, What About Net Loss?
InMed Pharmaceuticals Inc. (NASDAQ:INM) released financial results for the second quarter of fiscal year 2023 which ended December 31, 2022, revealing revenue of $469,783, a 77% increase compared to... 
Via Benzinga
InMed Reports Second Quarter Fiscal 2023 Financial Results and Provides Business Update
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
InMed Submits Form 12b-25
From InMed Pharmaceuticals Inc.
Via GlobeNewswire
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers Helbiz, Inc. (NASDAQ: HLBZ) shares jumped 133.1% to $0.2870. Helbiz recently announced discontinuation of operations in non-profitable markets. 
Via Benzinga
This Company's Rare Cannabinoids May Hold Promise In The Treatment Of Neurodegenerative Diseases Like Alzheimer's
Neurodegenerative diseases such as Parkinson’s, Alzheimer's and others are increasing worldwide as the population ages. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.